+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Schizophrenia"

Personalized Psychiatry - Product Thumbnail Image

Personalized Psychiatry

  • Book
  • October 2019
Social Cognition in Psychosis - Product Thumbnail Image

Social Cognition in Psychosis

  • Book
  • April 2019
Social Cognition and Metacognition in Schizophrenia - Product Thumbnail Image

Social Cognition and Metacognition in Schizophrenia

  • Book
  • October 2018
  • 354 Pages
Mental and Neurological Public Health - Product Thumbnail Image

Mental and Neurological Public Health

  • Book
  • August 2016
  • 560 Pages
Loading Indicator

Schizophrenia is a mental disorder characterized by abnormal social behavior and a distorted perception of reality. It is one of the most disabling and emotionally devastating mental illnesses, affecting approximately 1% of the population worldwide. Symptoms of schizophrenia can include hallucinations, delusions, disorganized speech and behavior, and cognitive deficits. The schizophrenia market within the context of mental health is a rapidly growing sector, driven by the increasing prevalence of the disorder and the need for better treatments. The market is expected to benefit from the development of novel drugs and therapies, as well as the increasing awareness of mental health issues. Additionally, the increasing focus on personalized medicine and the development of digital health technologies are expected to drive the market growth. Some of the key players in the schizophrenia market include Eli Lilly, Johnson & Johnson, Novartis, Pfizer, Otsuka Pharmaceutical, Sunovion Pharmaceuticals, Allergan, and Merck. Show Less Read more